Oppenheimer Initiates Coverage On Adverum Biotechnologies with Outperform Rating, Announces Price Target of $25
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer has initiated coverage on Adverum Biotechnologies (NASDAQ:ADVM) with an Outperform rating and a price target of $25.
June 25, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has initiated coverage on Adverum Biotechnologies with an Outperform rating and a price target of $25.
The initiation of coverage with an Outperform rating and a price target of $25 by a reputable analyst from Oppenheimer is likely to positively impact the stock price of Adverum Biotechnologies in the short term. This rating suggests strong potential for growth and could attract investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100